Niki BioSolutions, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Fewer than two of the last three years have both cash from operations and capital spending on file.
Your own DCF model
A full discounted-cash-flow model of Niki BioSolutions, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Biotechnology
Multiples of its companies with a market value at most 60 days old, times Niki BioSolutions, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Niki BioSolutions, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to book | 3.1× / 4.5× / 12.3× | — | book equity $23 M | $72 M to $285 M | 70 |
Against its own history
Niki BioSolutions, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Mar 2026, each against its own median.
Price to book
0.3×Now below its median of 1.0×, in the bottom quarter of its range; range 0.3× to 13.6× over 7 months.
As of Mar 8, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | — | $-1 M | $-2 M | — | — | — | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | — | $-4 M | $-1 M | — | — | — | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $0 M | $-3 M | $-8 M | $0 M | $-8 M | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $1 M | $-10 M | $-12 M | $0 M | $-13 M | $-5 M | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $2 M | $-25 M | $-15 M | $0 M | $-15 M | $-8 M | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | — | $5 M | $-16 M | $0 M | $-16 M | $-3 M | SEC annual report (10-K, 20-F) |